{"id":"modified-folfirinox","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Fatigue"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:03:00.948345","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The regimen consists of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin, which work together to inhibit DNA replication and induce apoptosis in cancer cells. This combination has been shown to be effective in treating various types of cancer, including pancreatic cancer.","oneSentence":"Modified FOLFIRINOX is a chemotherapy regimen that combines four drugs to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:56.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"}]},"_fixedFields":["pubmed(276)"],"trialDetails":[{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT07477418","phase":"PHASE1, PHASE2","title":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont","startDate":"2026-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms","enrollment":10},{"nctId":"NCT06445062","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-05-24","conditions":"Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma","enrollment":1130},{"nctId":"NCT04472910","phase":"NA","title":"GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-21","conditions":"Resectable Pancreatic Cancer","enrollment":84},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT06850623","phase":"PHASE2","title":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"EXACT Therapeutics AS","startDate":"2025-06-19","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":25},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT07026279","phase":"PHASE1, PHASE2","title":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Amplia Therapeutics Limited","startDate":"2025-08-18","conditions":"Pancreatic Cancer Metastatic","enrollment":67},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":"Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":150},{"nctId":"NCT02021422","phase":"PHASE1","title":"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2013-12","conditions":"Pancreas Cancer","enrollment":13},{"nctId":"NCT07407231","phase":"NA","title":"Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2021-09-01","conditions":"Locally Advanced Pancreatic Cancer","enrollment":18},{"nctId":"NCT07408505","phase":"NA","title":"Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2026-01-20","conditions":"Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome","enrollment":56},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT03983057","phase":"PHASE2","title":"Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":392},{"nctId":"NCT07214298","phase":"PHASE1, PHASE2","title":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-01","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":35},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT03977233","phase":"PHASE2","title":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT03322995","phase":"PHASE2","title":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2018-06-21","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT04161755","phase":"PHASE1","title":"Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-13","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT03991962","phase":"PHASE2","title":"Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2019-09-24","conditions":"Pancreatic Cancer","enrollment":28},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT06402864","phase":"PHASE3","title":"Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-03-26","conditions":"Adult With Intermediate Low or Mid Rectal Adenocarcinoma","enrollment":212},{"nctId":"NCT07043270","phase":"PHASE2","title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-09-29","conditions":"Pancreas Adenocarcinoma","enrollment":35},{"nctId":"NCT04888312","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alligator Bioscience AB","startDate":"2021-09-17","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":94},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT06896188","phase":"PHASE1","title":"9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2025-09-22","conditions":"Pancreatic Adenocarcinoma","enrollment":12},{"nctId":"NCT07096362","phase":"PHASE2","title":"Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-09-09","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":50},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT05585320","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immuneering Corporation","startDate":"2022-10-31","conditions":"Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)","enrollment":209},{"nctId":"NCT06249321","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Radiotherapy","enrollment":30},{"nctId":"NCT06149689","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-10","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT05132504","phase":"PHASE2","title":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-08-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06966440","phase":"NA","title":"Adjuvant Pancreatic Therapy Guided by MRD","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-01","conditions":"Pancreatic Adenocarcinoma Resectable","enrollment":856},{"nctId":"NCT06813976","phase":"PHASE3","title":"PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2025-07-02","conditions":"Ampullary Adenocarcinoma","enrollment":294},{"nctId":"NCT07034703","phase":"","title":"Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2025-09","conditions":"Resectable Pancreatic Duct Adenocarcinoma","enrollment":820},{"nctId":"NCT04292743","phase":"PHASE1","title":"Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2020-12-02","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":19},{"nctId":"NCT06897644","phase":"PHASE3","title":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-03-27","conditions":"Pancreatic Adenocarcinoma Advanced or Metastatic","enrollment":340},{"nctId":"NCT03750669","phase":"PHASE3","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-10-20","conditions":"Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy","enrollment":324},{"nctId":"NCT03374852","phase":"PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-08","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":""},{"nctId":"NCT06913218","phase":"PHASE1","title":"A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-07-22","conditions":"Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma","enrollment":60},{"nctId":"NCT05298722","phase":"NA","title":"Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2022-12-12","conditions":"Pancreatic Cancer","enrollment":45},{"nctId":"NCT06743386","phase":"NA","title":"Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )","status":"NOT_YET_RECRUITING","sponsor":"French Society of Digestive Endoscopy","startDate":"2025-04","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT06844422","phase":"PHASE1, PHASE2","title":"Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02-08","conditions":"Pancreatic Cancer","enrollment":37},{"nctId":"NCT05257993","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2022-03-30","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT03899636","phase":"PHASE3","title":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Angiodynamics, Inc.","startDate":"2021-02-23","conditions":"Stage III Pancreatic Cancer","enrollment":528},{"nctId":"NCT06538207","phase":"PHASE1","title":"An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-01-13","conditions":"Metastatic Pancreatic Cancer","enrollment":46},{"nctId":"NCT02672917","phase":"PHASE1","title":"Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies","status":"TERMINATED","sponsor":"BioNTech Research & Development, Inc.","startDate":"2016-01","conditions":"Pancreatic Cancer","enrollment":118},{"nctId":"NCT03699319","phase":"PHASE1, PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"David Bajor, MD","startDate":"2018-12-07","conditions":"Pancreatic Cancer","enrollment":49},{"nctId":"NCT04807972","phase":"PHASE1","title":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-05-28","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236},{"nctId":"NCT06532344","phase":"PHASE1","title":"An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-07-30","conditions":"Metastatic Pancreatic Cancer","enrollment":32},{"nctId":"NCT06389760","phase":"PHASE2","title":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-10-18","conditions":"Pancreatic Cancer","enrollment":57},{"nctId":"NCT06518538","phase":"PHASE2","title":"Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Cornerstone Pharmaceuticals","startDate":"2024-08-15","conditions":"Pancreatic Cancer Stage IV","enrollment":""},{"nctId":"NCT01595321","phase":"PHASE2","title":"Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-10-29","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT04672005","phase":"PHASE2","title":"Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lyudmyla Berim","startDate":"2021-01-06","conditions":"Metastatic Pancreatic Cancer","enrollment":30},{"nctId":"NCT06353581","phase":"PHASE2","title":"Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2022-02-16","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":78},{"nctId":"NCT06278545","phase":"PHASE2","title":"Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2024-02-16","conditions":"Locally Advanced or Metastatic Small Bowel Adenocarcinoma","enrollment":130},{"nctId":"NCT06151262","phase":"PHASE2","title":"A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-01-20","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT01959139","phase":"PHASE1, PHASE2","title":"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-01-23","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":126},{"nctId":"NCT06156267","phase":"EARLY_PHASE1","title":"Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT02231723","phase":"PHASE1","title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-08","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":139},{"nctId":"NCT06068023","phase":"","title":"The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.","status":"RECRUITING","sponsor":"Fondazione Poliambulanza Istituto Ospedaliero","startDate":"2023-07-01","conditions":"Ampullary Adenocarcinoma","enrollment":400},{"nctId":"NCT05070104","phase":"PHASE1","title":"CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Cornerstone Pharmaceuticals","startDate":"2023-03-30","conditions":"C04.588.274.476.411.307","enrollment":""},{"nctId":"NCT05926206","phase":"PHASE1, PHASE2","title":"Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2023-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":21},{"nctId":"NCT04990037","phase":"PHASE1","title":"A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cantargia AB","startDate":"2021-07-19","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT05868317","phase":"PHASE2","title":"Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer","status":"UNKNOWN","sponsor":"Salah Azaïz Cancer Institute","startDate":"2020-11-01","conditions":"Rectal Cancer, Locally Advanced","enrollment":70},{"nctId":"NCT03977272","phase":"PHASE2","title":"Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-03-27","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT03504423","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Cornerstone Pharmaceuticals","startDate":"2018-11-09","conditions":"Pancreatic Cancer Metastatic","enrollment":528},{"nctId":"NCT05665023","phase":"PHASE2","title":"Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2022-10-28","conditions":"Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":37},{"nctId":"NCT01926197","phase":"PHASE3","title":"Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-08-14","conditions":"Pancreatic Cancer","enrollment":27},{"nctId":"NCT03099265","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-06-26","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT02591030","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-12-15","conditions":"Bile Duct Cancer","enrollment":191},{"nctId":"NCT04617821","phase":"PHASE3","title":"AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT05066802","phase":"PHASE2","title":"A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-05-11","conditions":"Resectable Pancreatic Adenocarcinoma","enrollment":27},{"nctId":"NCT05007587","phase":"EARLY_PHASE1","title":"Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-07-01","conditions":"Hepatocellular Carcinoma Stage IIIa","enrollment":60},{"nctId":"NCT01676259","phase":"PHASE2","title":"A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Silenseed Ltd","startDate":"2018-03-07","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer","enrollment":80},{"nctId":"NCT03536182","phase":"PHASE3","title":"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-05-29","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT04835064","phase":"PHASE3","title":"Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-04-01","conditions":"Pancreatic Adenocarcinoma","enrollment":600},{"nctId":"NCT03778593","phase":"PHASE2","title":"FOLFIRINOX for 2nd-line Treatment of BTC","status":"COMPLETED","sponsor":"Dong-A University Hospital","startDate":"2019-03-01","conditions":"Biliary Tract Cancer","enrollment":34},{"nctId":"NCT04305288","phase":"","title":"Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-01-01","conditions":"Cholangiocarcinoma of the Bile Duct","enrollment":100},{"nctId":"NCT03042780","phase":"PHASE2","title":"FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-02-01","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas","enrollment":2},{"nctId":"NCT04611724","phase":"PHASE2","title":"A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2020-12-01","conditions":"Urachal Cancer","enrollment":35},{"nctId":"NCT01560949","phase":"PHASE2","title":"Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-14","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT01896869","phase":"PHASE2","title":"FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-11","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":83},{"nctId":"NCT02749136","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-05","conditions":"Pancreatic Adenocarcinoma","enrollment":44},{"nctId":"NCT02440958","phase":"PHASE2","title":"Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-08-28","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":50},{"nctId":"NCT03633734","phase":"PHASE1, PHASE2","title":"Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-07-01","conditions":"Pancreatic Adenocarcinoma Metastatic, Chemotherapy Effect","enrollment":49},{"nctId":"NCT03469375","phase":"","title":"Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2014-04-01","conditions":"Pancreatic Cancer, Chemotherapy Effect, Surgery--Complications","enrollment":41},{"nctId":"NCT01523457","phase":"PHASE2","title":"Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-10","conditions":"Metastatic Pancreatic Cancer, Pancreatic Cancer","enrollment":75},{"nctId":"NCT02575508","phase":"PHASE1, PHASE2","title":"Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Roswell Park Cancer Institute","startDate":"","conditions":"Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT01446458","phase":"PHASE1","title":"Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-11","conditions":"Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic","enrollment":13},{"nctId":"NCT01677988","phase":"PHASE2","title":"Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2012-07","conditions":"Adenocarcinoma of Head of Pancreas","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":276,"recentPublications":[{"date":"2026 Mar 2","pmid":"41893840","title":"Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms.","journal":"JAMA network open"},{"date":"2026 Mar 16","pmid":"41846177","title":"Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants.","journal":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"date":"2026 Feb","pmid":"41798502","title":"A Case of Recurrent Acute Pancreatitis After Gemcitabine + Nab-Paclitaxel and Modified FOLFIRINOX Therapy for Advanced Recurrent Pancreatic Cancer.","journal":"Cureus"},{"date":"2026 Feb","pmid":"41797455","title":"Peri-operative radiotherapy for pancreatic ductal adenocarcinoma: current evidence and future directions: a narrative review.","journal":"Chinese clinical oncology"},{"date":"2026 Mar","pmid":"41785438","title":"Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis.","journal":"JCO precision oncology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mFFX","modifiedFOLFIRINOX","mFOLFIRINOX"],"phase":"phase_3","status":"active","brandName":"modified FOLFIRINOX","genericName":"modified FOLFIRINOX","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Modified FOLFIRINOX is a chemotherapy regimen that combines four drugs to target rapidly dividing cancer cells. Used for Metastatic pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}